Company ProfilePremium

WeedOUT Ltd

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
WeedOUT Ltd - Company showcase

Year Founded & Workforce

2016

WeedOUT Ltd logo

WeedOUT Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

WeedOUT Ltd Overview

WeedOUT is an Israeli agricultural biotechnology developer. Its product is a species-specific biological herbicide that works through reproduction, not through plant toxicity. The method borrows the logic of the sterile insect technique, which has been used against flies and mosquitoes since the 1940s. The company:

  • grows male plants of a target weed;

  • harvests their pollen;

  • sterilises the pollen by irradiation;

  • releases it over infested fields.

The treated pollen fertilises female weed flowers but produces non-viable, aborted seed. This depletes the weed seedbank season after season. The first target is Palmer amaranth (Amaranthus palmeri), the most economically damaging herbicide-resistant weed in US cotton, soybean, corn and sugar beet. It is also a serious problem in Brazil and Argentina. WeedOUT positions the product as a complement to chemical programmes inside integrated weed management, not as a replacement. Its core value claim is that it attacks a complex reproductive process rather than a single enzyme pathway, which should make resistance harder to evolve. As of the latest public information, the company is pre-revenue and awaiting US EPA marketing approval.


What the company does

WeedOUT develops what it describes as the industry's first species-specific biological herbicide (AgFunder News, 2020). The production chain has four steps:

  1. Male plants of the target weed species are grown in controlled net houses. Palmer amaranth produces fresh pollen daily (AgWeb).

  2. The pollen is collected.

  3. The pollen is irradiated so it is sterile but still able to fertilise.

  4. Target weeds in the field are artificially pollinated with dispersing equipment, currently using a dry application (AgFunder 2020; AgWeb).

According to the company, its pollen has two key properties:

  • it competes successfully against naturally occurring weed pollen;

  • it still fertilises the ovule (Future Farming, 2024).

Co-founder Efrat Lidor Nili has told trade press that every seed formed after fertilisation with WeedOUT pollen is aborted (AgWeb). The company stresses that the pollen is exclusive to Palmer amaranth and does not affect row crops or other plants (AgWeb).

Company's own description

WeedOUT does not publish an annual report. In its February 2024 funding announcement, the company describes its technology as a novel, environmentally conscious way to sharply curb the spread of weeds that no longer respond to common chemical herbicides (Precision Farming Dealer, 2024). Startupim's owner-claimed profile adds three points:

  • the product is made with natural ingredients;

  • its aim is to reduce reliance on toxic herbicides and escalating doses;

  • it blocks the next generation of viable weed seeds through artificial pollination (Startupim raw profile).

Independent characterisation

WeedOUT is best described as a pre-commercial, single-asset biological crop-protection platform company. The platform claim rests on the idea that the sterile-pollen method can be repeated across other wind-pollinated, dioecious weeds. Palmer amaranth is a near-ideal first target for three reasons:

  • it is dioecious (separate male and female plants), so female flowers depend entirely on outside pollen;

  • it produces very large seed numbers per female plant, so cutting seed set has a compounding effect on the seedbank;

  • it has developed resistance to multiple herbicide modes of action.

The company is also developing formulations for other weed species (Produce Processing, 2024). It intends to extend first to other Amaranthus weeds (AgWeb); waterhemp (A. tuberculatus) is the logical next candidate, though the company has not publicly named it.

Mode of action. The product does not kill the treated plant. Management has acknowledged that a standing Palmer plant late in the season is probably already resistant. The treatment's job is to stop that plant from contributing viable seed (Farm Progress, 2020). The economic benefit is therefore multi-season seedbank reduction, not in-season yield protection. This has major consequences for how the product is sold, priced and demonstrated (see §10 and §22).

Business and revenue model

DimensionCharacterisationBasis
Revenue modelExpected product sales of treated pollen, possibly bundled with application services or equipment. No revenue disclosed.Inferred from product description; no disclosure
Product vs service vs subscription vs licensing mixNot publicly disclosed. Caplight lists the business model as B2B and the customer profile as "Hardware Sales"Caplight
Value-chain positionUpstream crop-protection input developer, analogous to a biological active-ingredient registrantIndependent characterisation
Customer typesCommercial row-crop growers (cotton, soybean, corn, sugar beet); likely routed through ag retailers or distributors and strategic partnersSeries A release (2024)
End-marketsUS Southeast and Midwest row crops first; Brazil and Argentina named as Palmer marketsGlobal AgInvesting (2024)
Go-to-marketNot publicly disclosed. The lead investor's network of US farmers is cited as an assetSeries A release (2024)

Strategy

Stated strategic themes (paraphrased from company communications)

  1. A biological, non-chemical answer to herbicide resistance. The company targets weed reproduction rather than a single enzymatic pathway, which management argues makes resistance harder to evolve. Its reference point is that sterility techniques in insects have shown no resistance problems in about 80 years (Series A release, 2024).

  2. Complement, not replace. Co-CEO Noivirt-Brik has framed the product as letting farmers integrate a biological approach with traditional methods (African Farming, 2024). This positions WeedOUT inside integrated weed management alongside herbicides, cover crops and harvest weed-seed control.

  3. Ecosystem compatibility. Because only weeds are treated with pollen, the method is designed to avoid threats to the food crop (Series A release, 2024).

  4. Platform expansion. New formulations for other weed species, beginning with other Amaranthus species (Produce Processing 2024; AgWeb).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDetailStatus
US field-trial expansionGeorgia, Nebraska and other regions; run with key opinion leaders in weed controlAnnounced Feb 2024; outcomes not published
EPA marketing approvalApplication for the Palmer amaranth productSubmitted by Feb 2024; approval not confirmed publicly
Manufacturing scale-upUpscaling pollen manufacturing, storage and applicationOngoing (AgWeb)
Pipeline formulationsOther weed speciesIn development

Public disclosure in this window is minimal. The announced initiatives date from the February 2024 round and are presumed to be ongoing:

Medium-term financial targets or guidance: not publicly disclosed.

ESG commitments: not formally published. The product itself is positioned as a green, herbicide-reducing solution.

Product Portfolio

Product / programmeDescriptionKey specifications / capabilitiesTarget customerStatus / yearPricing

Palmer amaranth sterile-pollen bioherbicide (commercial brand name not publicly disclosed)

Irradiated A. palmeri pollen applied by artificial pollination so female plants set aborted, non-viable seed

Species-specific to Palmer and does not affect row crops or other plants (AgWeb). Dry application; pollen is very light (AgWeb). Company states 100% abortion of seed formed after WeedOUT fertilisation (AgWeb). Competes with wild pollen (Future Farming 2024)

US cotton, soybean, corn and sugar beet growers; later Brazil and Argentina

EPA marketing-approval application submitted by Feb 2024. No public confirmation of approval found as of Oct 2026

—

Pollen production system (internal capability)

Net-house cultivation of male plants, daily pollen collection, irradiation, storage

Scale-up of manufacturing, storage and application under way (AgWeb)

Internal

Ongoing

—

Pollen dispersal / application equipment

Field dispersal equipment for artificial pollination

Caplight's "Hardware Sales" tag suggests possible equipment revenue. Unconfirmed

Growers / applicators

Development

—

Next-species formulations

New formulations for other weed species, extending first to other Amaranthus weeds

—

Row-crop growers

Development (2024 release)

—

“—” = not publicly disclosed.

Financial Narrative

Income statement

WeedOUT publishes no financial statements. The company is pre-commercial, so revenue is expected to be nil or immaterial. Even so, the revenue figure is not disclosed and is left blank rather than set to zero.

Revenue CAGR: not computable.

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are all not publicly disclosed or not computable. No underlying statements exist in the public domain.

Equity funding history — the only quantified financial data available

Commentary. Total disclosed capital is about USD 11–14M over roughly eight years. That is modest for a company seeking a novel EPA registration and building a biological manufacturing chain.

  • The roughly 3.3-year gap between the 2020 and 2024 rounds points to capital-efficient, trial-driven development, helped by Israeli grant support.

  • The 2024 round was earmarked for US trial expansion and launch preparation. Assuming a typical burn for an Israeli agbio company of this stage (not disclosed), the company would probably need further capital in 2026–2027 to fund commercial launch and manufacturing scale-up.

  • No public record of a post-2024 round was found as of October 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (Independent Characterisation) Overview

Segment (independent characterisation)Contents

Sterile-pollen bioherbicides — revenue (USD Mn; not publicly disclosed)

Palmer amaranth product; pipeline formulations for other weeds

Balance Sheet

MetricFY2019FY2020FY2021FY2022FY2023FY2024

Disclosed equity raised (USD Mn; Startupim round data)

0.253.00008.1

Round

Date

Amount (USD)

Lead

Other participants

Source

—

Competition-linked investment

c.2019

—

Radicle Growth (Radicle Challenge Israel prize)

—

Farm Progress (2020)

—

Seed

Oct 2019

0.25M

——

Startupim

—

Series A (first close)

Early 2020

—

Syngenta Ventures

—

AgFunder News (2020)

—

Series A

Nov 2020

3.0M

Not disclosed (likely the Syngenta-led round)

—

Startupim

—

Series A (extension)

20 Feb 2024

8.1M

Fulcrum Global Capital

Bunge Ventures; Clay Capital (formerly VisVires New Protein)

Global AgInvesting (2024); Caplight

—

Non-dilutive grants

Various

—

Israel Innovation Authority; EU Horizon 2020

—

AgFunder (2020); Future Farming (2024)

—

“—” = not publicly disclosed.

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable (unlisted)

Private valuation

Not publicly disclosed (Caplight secondary pricing paywalled)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

Not publicly disclosed; financing believed to be equity plus grants

Metric

FY2019

Cumulative disclosed equity raised (USD Mn; Startupim round data)

0.25

Analyst Conclusions

Management guidance

None published. The stated near-term objectives as of February 2024 were:

  • expand US field trials;

  • obtain EPA approval;

  • launch the inaugural Palmer amaranth product.

Consensus expectations

None (no coverage).

Bull case

  1. Resistance-proof mode of action at the right moment. Over-the-top dicamba registrations were vacated in 2024 (DTN), and growers face 263 resistant species globally (Global AgInvesting). A biological that attacks reproduction rather than an enzyme has a defensible, differentiated position.

  2. Strategic backing gives a distribution route. Syngenta Ventures led the first institutional round, and Bunge and Fulcrum's US farmer network joined later. That provides credible paths to licensing, distribution or acquisition without WeedOUT building a full sales force.

  3. Platform optionality. Once the pollen production, irradiation and dispersal chain is validated on Palmer, extending to waterhemp and other Amaranthus species could add major US Midwest acreage at incremental R&D cost.

Bear case

  1. Hard-to-sell benefit. The product does not kill the treated plant (Farm Progress, 2020), and payback comes from seedbank decline over several seasons. That is difficult to demonstrate and price against herbicides that show visible in-season kill.

  2. Scientific and scale risk. Syngenta's own managing director flagged that pollen may underperform the insect analogue (AgFunder, 2020). Pollen production depends on daily harvest from living plants (AgWeb). Efficacy and unit economics at commercial acreage remain unproven publicly.

  3. Time and capital. EPA approval had not been publicly confirmed more than 2.5 years after filing. No new financing has been disclosed since Feb 2024. Total disclosed funding is about USD 11–14M, and BASF is bringing new chemistry around 2027 (Iowa Farm Bureau, 2026). The company risks a funding squeeze before commercial proof.

Key catalysts and monitorables (next 12 months)

  1. EPA registration decision for the Palmer amaranth product.

  2. A new financing round (size, lead, any strategic participation, especially from Syngenta or Bayer).

  3. Publication of multi-season US field data (Georgia, Nebraska), ideally peer-reviewed or university-extension-validated.

  4. Commercial partnership, distribution or licensing agreement.

  5. Clarity on the December 2025 officeholder change.

  6. Announcement of a second target species.

  7. Regulatory filings in Brazil or Argentina.

Concluding analyst verdict

WeedOUT is a scientifically original, strategically well-sponsored, but still pre-commercial and thinly disclosed agricultural biotechnology venture. Its central insight is to turn Palmer amaranth's dependence on outside pollen into a weakness. That insight is elegant and matches a real, worsening agronomic crisis. Palmer can erase most of a crop's yield, and the chemical toolbox keeps shrinking, as the 2024 court vacatur of over-the-top dicamba registrations showed. Against that backdrop, a non-toxic, species-specific mode of action that should be robust to resistance is precisely what growers and regulators say they want. Investor quality is above average for its stage: Syngenta Ventures, Bunge Ventures and Fulcrum Global Capital give the company both validation and plausible exit or distribution routes.

The investment case nevertheless hinges on three unresolved questions that public information cannot yet answer:

Field performance: Does sterile pollen outcompete wild pollen enough, at realistic application rates, to cut seed return meaningfully in heavily infested commercial fields?

Manufacturing economics: Can a living, daily-harvested, irradiated input be produced, stored and delivered at a cost growers will pay for a benefit that appears only over several seasons?

Regulatory and financial runway: Will the company obtain EPA approval and raise follow-on capital before competing chemistries and investor patience run out?

It does not imply failure; the company remains registered and active. But it means the risk profile has not been visibly de-risked in over two and a half years. Verdict: high-potential, high-risk, binary early-stage asset. Its EPA decision and next financing round are the defining near-term events.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure

Efrat Lidor Nili, PhD

Co-founder and co-CEO

2016–present

Orly Noivirt-Brik, PhD

Co-founder and co-CEO

2016–present

Competitive Landscape

Key Competitors

#CompetitorCategoryApproachRelative positioning vs WeedOUT
1

Bayer Crop Science

Chemical / traits incumbent

Herbicides and herbicide-tolerant traits

Scale incumbent. Over-the-top dicamba setback (2024) highlights a vulnerability

2

Syngenta Group

Chemical incumbent

Herbicide portfolio

Also a WeedOUT investor: competitor and potential partner

3

BASF Agricultural Solutions

Chemical incumbent

New all-in-one herbicide targeting 2027 availability

Direct substitute in the Palmer programme budget

4

Corteva Agriscience

Chemical / traits incumbent

Herbicides and tolerant traits

Scale incumbent

5

FMC Corporation

Chemical incumbent

Pre-emergent herbicides and new modes of action

Incumbent with new-chemistry pipeline

6

Moa Technology (UK)

Novel herbicide discovery start-up

New herbicide modes of action

Competing "new mode of action" narrative

7

Micropep Technologies (France)

Biological start-up

Peptide-based crop protection, including weeds

Peer in biological herbicides

8

Harpe Bio (US)

Bioherbicide start-up

Natural-product herbicides

Peer in biological herbicides

9

Carbon Robotics (US)

Mechanical / robotic

Laser weeding

Non-chemical alternative, mainly specialty crops

10

Greeneye Technology (Israel)

Precision spraying

AI-driven targeted herbicide application

Reduces herbicide volume; does not solve resistance

11

Harvest weed-seed control (e.g., Redekop Seed Control Unit, Harrington Seed Destructor)

Mechanical seedbank control

Destroys weed seed at harvest

Closest functional analogue. Also attacks the seedbank

Key Competitors by Company

CompanyRevenue

WeedOUT

Not publicly disclosed (pre-revenue)

Bayer Crop Science

Not compiled in this research

Syngenta Group

Not compiled in this research

BASF Agricultural Solutions

Not compiled in this research

Recent Developments

The verifiable items, plus the most recent pre-window anchors for context, are shown below.

Company Snapshot

2016

Founded

Center District, Israel

Headquarters

SWOT Analysis

Strengths

  • Novel mode of action. Targets reproduction rather than a single enzyme pathway (co-CEO statement, 2024 release), giving a credible resistance-robustness thesis.
  • High specificity. Pollen is exclusive to Palmer and does not affect crops or other plants (AgWeb), so there is no crop-injury or drift liability, unlike dicamba.
  • Strategic investor validation. Series A led by Syngenta Ventures (2020); Bunge Ventures participated (2024).
  • Grower-network investor. Fulcrum Global Capital brings an extensive US farmer network (2024 release).
  • Non-dilutive funding track record. Multiple IIA grants plus EU Horizon 2020 (AgFunder 2020; Future Farming 2024).
  • Regulatory progress. EPA marketing-approval application filed by Feb 2024.
  • Early external validation. AgriVest 2018 award and Radicle Challenge Israel win.

Weaknesses

  • No in-season control. Management concedes treated late-season plants are likely resistant and survive; the benefit is the seedbank only (Farm Progress, 2020).
  • Single-species product at launch. Palmer only (AgWeb).
  • Modest capital base. Total disclosed funding of about USD 11–14M (Startupim and Caplight).
  • Living-input manufacturing. Daily pollen harvest from net-house plants plus irradiation and storage (AgWeb), which is complex to scale.
  • Efficacy concerns raised by its own investor. Pollen may be less effective than sterile insects (Syngenta Ventures, AgFunder 2020).
  • Opaque disclosure. No published peer-reviewed field data, headcount or commercial timeline located.

Opportunities

  • Extension to other Amaranthus weeds, waterhemp in particular (AgWeb; Iowa Farm Bureau 2026).
  • Latin America. Palmer is a major problem in Brazil and Argentina (Global AgInvesting, 2024).
  • Regulatory loss of chemical options. 2024 vacatur of over-the-top dicamba registrations (DTN).
  • Partnership or licensing with Syngenta or other majors for distribution.
  • Bundling with harvest weed-seed control and pre-emergent programmes as a seedbank-management package.
  • Sustainability-linked demand for lower herbicide loads.

Threats

  • New chemistry. BASF all-in-one herbicide expected in 2027 (Iowa Farm Bureau, 2026).
  • Regulatory delay. EPA approval not publicly confirmed more than 2.5 years after filing. PRIA statutory timelines can be long, as DTN noted for dicamba.
  • Wild-pollen competition diluting efficacy in heavily infested fields.
  • Funding risk. No disclosed round since Feb 2024.
  • Israel-specific operating risk. Regional security conditions since 2023 may affect operations; this is a general consideration, not company-specific disclosure.
  • Grower adoption inertia toward products without visible in-season kill.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
20–28 Feb 2024 (pre-window anchor)USD 8.1M Series A extension. EPA application disclosed. US trials expanded to Georgia and Nebraska Global AgInvesting; Produce ProcessingLast major public corporate announcement
2024 (pre-window, industry)US District Court in Arizona vacates 2020 registrations of over-the-top dicamba products (XtendiMax, Engenia, Tavium); EPA does not appeal DTN (Dec 2024)Narrows chemical options against resistant Palmer and strengthens the case for new modes of action
14 Dec 2025Israeli registry records an officeholder update at WeedOUT StartupimPossible board or management change; details undisclosed
13 Apr 2026 (industry)Iowa Farm Bureau reports Palmer amaranth and waterhemp outpacing control tools. BASF moving to EPA registration of a new all-in-one herbicide expected in 2027 Iowa Farm Bureau (2026)Confirms that the problem is growing; shows a chemical competitor advancing
May 2026Startupim profile updated; status active; profile claimed by ownerCompany remains operating
Aug 2026Startupim profile updated; status active; total raised listed as USD 13.5MNo new round recorded
As of Oct 2026No public confirmation found of EPA registration, commercial launch, new financing, or published trial results This researchKey information gap

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Balance Sheet: Disclosed equity raised rose from USD 0.3 Mn in FY2019 to USD 8.1 Mn in FY2024.
WeedOUT Ltd — Balance Sheet
Series (USD Mn)FY2019FY2020FY2021FY2022FY2023FY2024
Disclosed equity raised0.330008.1
Competition-linked investment2,019—————

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Global AgInvesting, "WeedOUT Raises $8.1M Series A to Combat Weed Resistance," 21 Feb 2024 (globalaginvesting.com)
  2. Future Farming, "Start-up WeedOUT raises $8.1 million to fight weed resistance," 2024 (futurefarming.com)
  3. Asia Food Journal, "Ag-tech Start-Up WeedOUT Raises USD8.1 Million," 21 Feb 2024 (asiafoodjournal.com)
  4. Produce Processing, "Ag tech startup secures funding for solution targeting herbicide-resistant weeds," 28 Feb 2024 (produceprocessing.net)
  5. Precision Farming Dealer, "Startup WeedOUT Raises $8.1 Million," 2024 (precisionfarmingdealer.com)
  6. African Farming, "WeedOUT raises US$8.1mn to combat weed resistance," 2024 (africanfarming.net)
  7. AgroSpectrum India, "Ag-tech start-up WeedOUT raises USD8.1 Mn," 2024 (agrospectrumindia.com)
  8. AgFunder News, "Syngenta leads Series A for WeedOut to commercialize first species-specific biological herbicide," 2020 (agfundernews.com)
  9. Farm Progress, "Tackling resistant weeds in a new way," 30 Mar 2020 (farmprogress.com)
  10. AgWeb, "Killing the Weed King: Could Groundbreaking Pollen Technology Control Palmer Amaranth?" (agweb.com)
  11. Caplight, WeedOUT Ltd. company profile (caplight.com)
  12. Startupim, WeedOUT profile (updated Aug 2026) (startupim.com)
  13. Startupim, WeedOUT raw profile (updated May 2026) (startupim.com)
  14. VCBacked, WeedOut profile (vcbacked.co)
  15. DTN, "Top 10 Ag Stories of 2024: 'Over-the-Top' Dicamba Product Registrations Vacated," 19 Dec 2024 (dtnpf.com)
  16. Iowa Farm Bureau, "Palmer amaranth, waterhemp outpace control tools," 13 Apr 2026 (iowafarmbureau.com)
  17. University of Georgia CAES Field Report, "U.S. EPA extends registration of weed killer dicamba" (fieldreport.caes.uga.edu)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.